PHILIPPE BIERLING, M.D.; CATHERINE CORDONNIER, M.D.; NAJIB DUEDARI, M.D.; JEAN-PAUL VERNANT, M.D.; JACQUES LEIBOWITCH, M.D.; DOMINIQUE MATHEZ, M.D.
This content is PDF only. Please click on the PDF icon to access.
To the editor: The acquired immunodeficiency seen after bone marrow transplantation and that due to infection with the lymphadenopathy-associated virus/human T-lymphotropic virus type HI (LAV/HTLV-III) have many clinical and immunologic features in common. Marrow transplant recipients are at risk of LAV/HTLV-III infection given the considerable amount of transfused blood products they receive. A retrospective study was conducted in our institution to determine the role of LAV/HTLV-III in the immunodeficiency seen after bone marrow transplantation.
Fifty unselected patients, for whom a serum sample collected at least 100 days after bone marrow transplantation was available, were included. All patients received an allogeneic
BIERLING P, CORDONNIER C, DUEDARI N, VERNANT J, LEIBOWITCH J, MATHEZ D. Lymphadenopathy-Associated Virus/Human T-Lymphotropic Virus Type III in Allogeneic Bone Marrow Transplantation. Ann Intern Med. ;104:131–132. doi: 10.7326/0003-4819-104-1-131
Download citation file:
Published: Ann Intern Med. 1986;104(1):131-132.
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use